We explore the use of different radio galaxy populations as tracers of different mass haloes and therefore, with different bias properties, to constrain primordial non-Gaussianity of the local type. ...We perform a Fisher matrix analysis based on the predicted auto- and cross-angular power spectra of these populations, using simulated redshift distributions as a function of detection flux and the evolution of the bias for the different galaxy types (star-forming galaxies, starburst galaxies, radio-quiet quasars, FR I and FR II AGN galaxies). We show that such a multitracer analysis greatly improves the information on non-Gaussianity by drastically reducing the cosmic variance contribution to the overall error budget. By applying this method to future surveys, we predict a constraint of σ f
nl = 3.6 on the local non-Gaussian parameter for a galaxy detection flux limit of 10 μJy and σ f
nl = 2.2 for 1 μJy. We show that this significantly improves on the constraints obtained when using the whole undifferentiated populations (σ f
nl = 48 10 μJy and σ f
nl = 12 for 1 μJy). We conclude that continuum radio surveys alone have the potential to constrain primordial non-Gaussianity to an accuracy at least a factor of 2 better than the present constraints obtained with Planck data on the cosmic microwave background bispectrum, opening a window to obtain σ f
nl ∼ 1 with the Square Kilometre Array.
•The mainstay of treatment for locally advanced rectal cancer is (chemo) radiotherapy and surgery.•Trials have not given clear indications on the added value of adjuvant chemotherapy.•A risk-adapted ...algorithm should be considered in clinical practice.•Pros and cons of adjuvant chemotherapy should be discussed with ypStage II and III patients.•Patients should be informed of the evidence gap and be empowered in the decision making.
While adjuvant chemotherapy is an established treatment for pathological stage II and especially stage III colon cancer, its role in the multimodal management of rectal cancer remains controversial. As a result, there is substantial variation in the use of this treatment in clinical practice. Even among centres and physicians who consider adjuvant chemotherapy as a standard treatment, notable heterogeneity exists with regard to patient selection criteria and chemotherapy regimens. The controversy around this topic is confirmed by the lack of full consensus among national and international clinical guidelines. While most of the clinical trials do not support the contention that adjuvant chemotherapy may improve survival outcomes if pre-operative (chemo)radiotherapy is also given, these suffer from many limitations that preclude drawing definitive conclusions. Nevertheless, in the era of evidence-based medicine, physicians should be guided by the available data and refrain from extrapolating results of adjuvant colon cancer trials to inform treatment decisions for rectal cancer. Patients should be informed of the evidence gap, be given the opportunity to carefully discuss pros and cons of all the possible management options and be empowered in the decision making. In this article we review the available evidence on adjuvant chemotherapy for rectal cancer and propose a risk-adapted decisional algorithm that largely relies on informed patient preferences.
In recent years, forecasting activities have become an important tool in designing and optimising large-scale structure surveys. To predict the performance of such surveys, the Fisher matrix ...formalism is frequently used as a fast and easy way to compute constraints on cosmological parameters. Among them lies the study of the properties of dark energy which is one of the main goals in modern cosmology. As so, a metric for the power of a survey to constrain dark energy is provided by the figure of merit (FoM). This is defined as the inverse of the surface contour given by the joint variance of the dark energy equation of state parameters {
w
0
,
w
a
} in the Chevallier-Polarski-Linder parameterization, which can be evaluated from the covariance matrix of the parameters. This covariance matrix is obtained as the inverse of the Fisher matrix. The inversion of an ill-conditioned matrix can result in large errors on the covariance coefficients if the elements of the Fisher matrix are estimated with insufficient precision. The conditioning number is a metric providing a mathematical lower limit to the required precision for a reliable inversion, but it is often too stringent in practice for Fisher matrices with sizes greater than 2 × 2. In this paper, we propose a general numerical method to guarantee a certain precision on the inferred constraints, such as the FoM. It consists of randomly vibrating (perturbing) the Fisher matrix elements with Gaussian perturbations of a given amplitude and then evaluating the maximum amplitude that keeps the FoM within the chosen precision. The steps used in the numerical derivatives and integrals involved in the calculation of the Fisher matrix elements can then be chosen accordingly in order to keep the precision of the Fisher matrix elements below this maximum amplitude. We illustrate our approach by forecasting stage IV spectroscopic surveys cosmological constraints from the galaxy power spectrum. We infer the range of steps for which the Fisher matrix approach is numerically reliable. We explicitly check that using steps that are larger by a factor of two produce an inaccurate estimation of the constraints. We further validate our approach by comparing the Fisher matrix contours to those obtained with a Monte Carlo Markov chain (MCMC) approach – in the case where the MCMC posterior distribution is close to a Gaussian – and finding excellent agreement between the two approaches.
We compare Mercury’s precession test in standard general relativity, Brans–Dicke theories (BD), and Palatini
f
(
R
)
-theories. We avoid post-Newtonian approximation and compute exact precession in ...these theories. We show that the well-known mathematical equivalence between Palatini
f
(
R
)
-theories and a specific subset of BD theories does not extend to a really physical equivalence among theories since equivalent models still allow a different incompatible precession for Mercury depending on the solution one chooses. As a result one cannot use BD equivalence to rule out Palatini
f
(
R
)
-theories. On the contrary, we directly discuss that Palatini
f
(
R
)
-theories can (and specific models do) easily pass Solar System tests as Mercury’s precession.
ABSTRACT
Covering $\sim 5600\, \deg ^2$ to rms sensitivities of ∼70−100 $\mu$Jy beam−1, the LOFAR Two-metre Sky Survey Data Release 2 (LoTSS-DR2) provides the largest low-frequency (∼150 MHz) radio ...catalogue to date, making it an excellent tool for large-area radio cosmology studies. In this work, we use LoTSS-DR2 sources to investigate the angular two-point correlation function of galaxies within the survey. We discuss systematics in the data and an improved methodology for generating random catalogues, compared to that used for LoTSS-DR1, before presenting the angular clustering for ∼900 000 sources ≥1.5 mJy and a peak signal-to-noise ≥ 7.5 across ∼80 per cent of the observed area. Using the clustering, we infer the bias assuming two evolutionary models. When fitting angular scales of $0.5 \le \theta \lt 5{^\circ }$, using a linear bias model, we find LoTSS-DR2 sources are biased tracers of the underlying matter, with a bias of $b_{\rm C}= 2.14^{+0.22}_{-0.20}$ (assuming constant bias) and $b_{\rm E}(z=0)= 1.79^{+0.15}_{-0.14}$ (for an evolving model, inversely proportional to the growth factor), corresponding to $b_{\rm E}= 2.81^{+0.24}_{-0.22}$ at the median redshift of our sample, assuming the LoTSS Deep Fields redshift distribution is representative of our data. This reduces to $b_{\rm C}= 2.02^{+0.17}_{-0.16}$ and $b_{\rm E}(z=0)= 1.67^{+0.12}_{-0.12}$ when allowing preferential redshift distributions from the Deep Fields to model our data. Whilst the clustering amplitude is slightly lower than LoTSS-DR1 (≥2 mJy), our study benefits from larger samples and improved redshift estimates.
Osteoporosis is a complication of chronic liver disease, with impact on morbidity, quality of life, and survival. The progress of medicine and the new therapies stretched the disease’s natural ...history and improved the survival of patients with liver disease. So, it is fundamental to make better the quality of life and to prevent complications. Metabolic bone disorders are common complications of chronic liver disease (CLD). Patients with CLD have an increased risk of bone fractures, with significant impact on morbidity, quality of life, and even on survival. Bone diseases, including osteomalacia, osteoporosis, and osteopenia, are frequently observed in many types of liver disease. The pathogenesis of damage and the mechanisms of bone loss are different in relation to the specific liver disease. The relevance of these conditions induced many authors to create a new nosographic entity known as “hepatic osteodystrophy”, although this term is rarely used anymore and it is now commonly referred to as osteopenia or osteoporosis associated with chronic liver disease. This review is based on the personal experiences of the authors and upon research done of the available literature on this subject matter. The authors searched the PubMed database for publications containing the term “liver disease” in combination with “bone disease”, “hepatic osteodistrophy”, “osteoporosis”, “osteopenia”, “osteomalacia”, and “fractures”. They selected publications from the past 10 years but did not exclude older seminal publications, especially for colestatic liver diseases. This review of literature shows that osteoporosis crosses all CLD. It is important to underline that the progress of medicine and the new therapies stretched the disease’s natural history and improved the survival of patients with CLD. It is fundamental to make better the quality of life and it is mandatory to prevent complications and in particular the osteoporotic ones, especially fractures.
We previously reported that patatin-like protein 2 (PLP2), a pathogen-induced patatin-like lipid acyl hydrolase, promotes cell death and negatively affects Arabidopsis resistance to the fungus ...Botrytis cinerea and to the bacteria Pseudomonas syringae. We show here that, on the contrary, PLP2 contributes to resistance to Cucumber mosaic virus, an obligate parasite inducing the hypersensitive response. These contrasted impacts on different pathosystems were also reflected by differential effects on defense gene induction. To examine a possible link between PLP2 lipolytic activity and oxylipin metabolism, gene expression profiling was performed and identified B. cinerea among these pathogens as the strongest inducer of most oxylipin biosynthetic genes. Quantitative oxylipin profiling in wild-type and PLP2-modified, Botrytis-challenged plants established the massive accumulation of oxidized fatty acid derivatives in infected leaves. Several compounds previously described as modulating plant tissue damage and issued from the α-dioxygenase pathway were found to accumulate in a PLP2-dependent manner. Finally, the contribution of PLP2 to genetically controlled cell death was evaluated using PLP2-silenced or -overexpressing plants crossed with the lesion mimic mutant vascular-associated death 1 (vad1). Phenotypic analysis of double-mutant progeny showed that PLP2 expression strongly promotes necrotic symptoms in vad1 leaves. Collectively, our data indicate that PLP2 is an integral component of the plant cell death execution machinery, possibly providing fatty acid precursors for the biosynthesis of specific oxylipins and differentially affecting resistance to pathogens with distinct lifestyles.
•Disagreement between rectal cancer guidelines exists in 62% of relevant topics.•High level of evidence exists for 20% of topics where guidelines are in agreement.•High level of evidence exists for ...63% of topics where guidelines are in disagreement.•Disagreement is more frequent for treatment-related topics.
While the management of nonmetastatic and oligometastatic rectal cancer has rapidly evolved over the last few decades, many grey areas and highly debated topics remain that foster significant variation in clinical practice. We aimed to identify controversial points and evidence gaps in this disease setting by systematically comparing recommendations from national and international clinical guidelines.
Twenty-six clinical questions reflecting practical challenges in the routine management of nonmetastatic and oligometastatic rectal cancer patients were selected. Recommendations from the ESMO, NCCN, JSCCR, Australian and Ontario guidelines were extrapolated and compared using a 4-tier classification system (i.e., identical/very similar, similar, slightly different, different). Overall agreement between guidelines (i.e., substantial/complete disagreement, partial disagreement, partial agreement, substantial/complete agreement) was assessed for each clinical question and compared against the highest level of available evidence by using the χ2 statistic test.
Guidelines were in substantial/complete agreement, partial agreement, partial disagreement, and substantial/complete disagreement for 8 (30.8%), 2 (7.7%), 7 (26.9%), and 9 (34.6%) clinical questions, respectively. High level of evidence supported clinical recommendations in 3/10 cases (30%) where guidelines were in agreement and in 10/16 cases (62.5%) where guidelines were in disagreement (χ2 = 2.6, p = 0.106). Agreement was frequently reached for questions regarding diagnosis, staging, and radiology/pathology pro-forma reporting, while disagreement characterised most of the treatment-related topics.
Substantial variation exists across clinical guidelines in the recommendations for the management of nonmetastatic and oligometastatic rectal cancer. This variation is only partly explained by the lack of supporting, high-level evidence.
PDF
